Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$66.80 -1.1%	$70.38	$38.57 ▼ $84.94	$13.23B	0.97	2.71 million shs	1.55 million shs
RVMD Revolution Medicines	$153.87 +3.1%	$139.66	$34.00 ▼ $166.50	$31.73B	1.4	2.79 million shs	1.58 million shs
TAK Takeda Pharmaceutical	$15.92 +0.3%	$16.78	$12.99 ▼ $18.90	$50.51B	-0.07	2.99 million shs	3.97 million shs
TEVA Teva Pharmaceutical Industries	$34.58 +0.0%	$33.28	$14.99 ▼ $37.35	$39.74B	0.84	5.70 million shs	5.93 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.22%	+0.33%	+2.43%	-2.68%	+72.98%
RVMD Revolution Medicines	+3.50%	-4.15%	+2.41%	+57.32%	+265.85%
TAK Takeda Pharmaceutical	+1.19%	+2.91%	-3.28%	-10.52%	+4.63%
TEVA Teva Pharmaceutical Industries	+3.01%	+0.49%	-3.52%	+21.08%	+99.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$66.80 -1.1%	$70.38	$38.57 ▼ $84.94	$13.23B	0.97	2.71 million shs	1.55 million shs
RVMD Revolution Medicines	$153.87 +3.1%	$139.66	$34.00 ▼ $166.50	$31.73B	1.4	2.79 million shs	1.58 million shs
TAK Takeda Pharmaceutical	$15.92 +0.3%	$16.78	$12.99 ▼ $18.90	$50.51B	-0.07	2.99 million shs	3.97 million shs
TEVA Teva Pharmaceutical Industries	$34.58 +0.0%	$33.28	$14.99 ▼ $37.35	$39.74B	0.84	5.70 million shs	5.93 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.22%	+0.33%	+2.43%	-2.68%	+72.98%
RVMD Revolution Medicines	+3.50%	-4.15%	+2.41%	+57.32%	+265.85%
TAK Takeda Pharmaceutical	+1.19%	+2.91%	-3.28%	-10.52%	+4.63%
TEVA Teva Pharmaceutical Industries	+3.01%	+0.49%	-3.52%	+21.08%	+99.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.85	Moderate Buy	$89.59	34.12% Upside
RVMD Revolution Medicines	3.00	Buy	$123.72	-19.59% Downside
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$41.78	20.83% Upside

Current Analyst Ratings Breakdown

Latest BBIO, TAK, TEVA, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2026	BBIO BridgeBio Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$104.00
6/2/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$165.00 ➝ $182.00
6/1/2026	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$169.00 ➝ $195.00
6/1/2026	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/1/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$165.00 ➝ $195.00
5/28/2026	BBIO BridgeBio Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$94.00 ➝ $98.00
5/28/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
5/26/2026	BBIO BridgeBio Pharma	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/21/2026	RVMD Revolution Medicines	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$151.00
5/21/2026	RVMD Revolution Medicines	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
5/19/2026	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$82.00

(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	26.06	N/A	N/A	($10.77) per share	-6.20
RVMD Revolution Medicines	$11.58M	2,824.94	N/A	N/A	$8.44 per share	18.23
TAK Takeda Pharmaceutical	$28.32B	1.79	$3.11 per share	5.11	$16.12 per share	0.99
TEVA Teva Pharmaceutical Industries	$17.26B	2.30	$3.73 per share	9.27	$6.88 per share	5.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.74	N/A	290.43	N/A	-124.42%	N/A	-65.81%	8/4/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$7.07	N/A	N/A	N/A	N/A	-83.22%	-59.06%	8/5/2026 (Estimated)
TAK Takeda Pharmaceutical	$1.27B	$0.39	40.81	13.05	N/A	4.31%	11.07%	5.49%	7/30/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	26.00	11.37	3.53	9.01%	43.53%	8.19%	7/29/2026 (Estimated)

Latest BBIO, TAK, TEVA, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	BBIO BridgeBio Pharma	-$0.70	-$0.84	-$0.14	-$0.84	$178.07 million	$194.52 million
5/6/2026	Q1 2026	RVMD Revolution Medicines	-$1.83	-$2.29	-$0.46	-$2.29	$2.43 million	N/A
4/29/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	$0.50	$0.53	+$0.03	$0.31	$3.79 billion	$3.98 billion
3/31/2026	Q4 2025	TAK Takeda Pharmaceutical	N/A	$0.5610	N/A	-$0.0483	N/A	$6.90 billion
3/31/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.53	N/A	$0.31	N/A	$3.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.25	1.57%	-18.61%	64.10%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.52	1.48
RVMD Revolution Medicines	0.19	6.80	6.80
TAK Takeda Pharmaceutical	0.56	1.27	0.70
TEVA Teva Pharmaceutical Industries	1.70	1.01	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
RVMD Revolution Medicines	94.34%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
RVMD Revolution Medicines	7.60%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	195.86 million	167.99 million	Optionable
RVMD Revolution Medicines	250	212.60 million	196.44 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable

BBIO, TAK, TEVA, and RVMD Headlines

Recent News About These Companies

2 hours ago | fool.com

Teva Pharmaceutical closes acquisition of Emalex Biosciences

June 12 at 9:05 AM | pharmabiz.comP

173,075 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Marsico Capital Management LLC

June 12 at 7:06 AM | marketbeat.com

Private Management Group Inc. Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

June 12 at 4:41 AM | marketbeat.com

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

June 11 at 6:33 PM | finance.yahoo.com

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

June 11 at 3:03 PM | businesswire.com

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

June 10 at 1:52 PM | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. Completes Acquisition of Emalex Biosciences to Enhance Tourette Syndrome Treatment Pipeline with Ecopipam

June 10 at 12:10 PM | quiverquant.comQ

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

June 10 at 12:03 PM | globenewswire.com

Teva’s data on Austedo highlight long-term advances in treatment of tardive dyskinesia

June 10 at 8:52 AM | pharmabiz.comP

TIAA Trust National Association Sells 237,843 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

June 10 at 7:32 AM | marketbeat.com

2,361,012 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Capital World Investors

June 10 at 3:51 AM | marketbeat.com

Is Amneal a Buy Before Rytary Generic Erosion?

June 9 at 2:56 PM | finance.yahoo.com

TD Asset Management Inc Purchases 118,075 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

June 9 at 4:59 AM | marketbeat.com

Capital International Investors Raises Stake in Teva Pharmaceutical Industries Ltd. $TEVA

June 9 at 3:25 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Lowers Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

June 9 at 3:09 AM | marketbeat.com

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

June 9 at 1:02 AM | finance.yahoo.com

Teva Pharmaceutical Industries Ltd: Teva's Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in ...

June 8, 2026 | finanznachrichten.de

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

June 8, 2026 | finance.yahoo.com

Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?

June 8, 2026 | finance.yahoo.com

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

June 8, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BBIO, TAK, TEVA, and RVMD Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$66.80 -0.75 (-1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$66.81 +0.01 (+0.01%)

As of 05:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Revolution Medicines NASDAQ:RVMD

$153.87 +4.64 (+3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$153.69 -0.18 (-0.12%)

As of 07:58 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Takeda Pharmaceutical NYSE:TAK

$15.92 +0.05 (+0.28%)

Closing price 03:59 PM Eastern

Extended Trading

$16.01 +0.10 (+0.60%)

As of 06:31 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$34.58 +0.02 (+0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$34.57 0.00 (0.00%)

As of 08:00 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBIO, TAK, TEVA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBIO, TAK, TEVA, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBIO, TAK, TEVA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBIO, TAK, TEVA, and RVMD Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Revolution Medicines NASDAQ:RVMD

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBIO, TAK, TEVA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBIO, TAK, TEVA, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBIO, TAK, TEVA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BBIO, TAK, TEVA, and RVMD Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Revolution Medicines NASDAQ:RVMD

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools